Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
07 Setembro 2023 - 8:00AM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical
company aiming to transform the lives of patients by establishing
intracellular Endosomal Escape Vehicle (EEVÔ) therapeutics as a new
class of medicines, today announced recipients of its inaugural
Entrada
Diversity,
Representation,
Equity and
Advocacy
Matter
S
(DREAMS) Grant Program. Entrada DREAMS grant recipients – The Akari
Foundation, Neurology and Neuromuscular Care Center and Parent
Project Muscular Dystrophy (PPMD) – will each be awarded $25,000 to
support initiatives that aim to better identify, understand and
reach those within the Duchenne community who are currently
underrepresented or underserved.
“Building on the power of World Duchenne
Awareness Day, we’re thrilled to support the Duchenne community and
those working to combat disparity in healthcare by awarding funding
to three leading non-profit organizations that embody the mission
of the DREAMS Grant Program,” said Dipal Doshi, President and Chief
Executive Officer at Entrada Therapeutics. “These organizations are
breaking barriers to improve diversity, equity, inclusion and
accessibility, and we look forward to seeing their work in action
as they continue to make a meaningful difference for the Duchenne
community.”
Entrada DREAMS Grant
Recipients
- The Akari Foundation is a
non-profit organization dedicated to educating and empowering the
Hispanic community about rare diseases, with a focus on Duchenne.
Its mission is to provide resources, awareness, advocacy and
education to affected families entirely in Spanish. Funds provided
by Entrada DREAMS will help Akari to empower individuals and
families living with Duchenne through greater disease awareness and
educational resources, while helping to foster a more inclusive
society that celebrates diversity and provides equal opportunities
for all.
- Neurology and Neuromuscular Care
Center is a non-profit private practice led by Dr. Diana Castro
with the mission to provide care to all patients with neuromuscular
conditions like Duchenne, especially those from minority
backgrounds who are currently underserved, uninsured or
underinsured. Funding provided by Entrada will support the clinic
in hiring its first mental health professional. This individual
will help to address gaps in socioeconomic health needs by
providing emotional and social support to people and families
living with Duchenne.
- Parent Project Muscular Dystrophy
(PPMD) Foundation is a patient advocacy organization fighting to
end Duchenne by helping those living with the condition to lead
longer, stronger lives. The Entrada DREAMS grant will help PPMD
further its work to address disparity within the Duchenne
community’s access to care and research opportunities based on
racial, geographic and socioeconomic diversity.
Entrada thanks the panel of expert reviewers who
selected the Entrada DREAMS grant recipients in this inaugural year
of the program, including:
- Sean Baumstark, Founder, de:terminence and
Co-Host, Two Disabled Dudes Podcast
- Keisha Greaves, Founder and Chief Executive
Officer, Girls Chronically Rock
- Hugo Trevino, MEd, Disability Services
Specialist, University of Illinois at Chicago
- Aravindhan Veerapandiyan, MD (Dr. Panda),
Assistant Professor of Pediatrics, Division of Pediatric Neurology,
Arkansas Children’s Hospital
“I’m honored to have had the opportunity to
serve on the Review Committee for the Entrada DREAMS Grant
Program’s inaugural year,” said Sean Baumstark, Founder of
de:terminence and Co-Host of Two Disabled Dudes Podcast. “There’s
no shortage of remarkable organizations in the Duchenne community,
but this year’s recipients are leading the charge with their
commitment to serving those who are currently underrepresented and
in need of additional support and resources. On behalf of the
DREAMS Review Committee, we congratulate these three vital
organizations and we look forward to seeing the lasting impact that
their work will continue to have on the Duchenne community.”
About Entrada DREAMS Grant
ProgramEntrada DREAMS is a competitive grants program
designed to fund efforts within the Duchenne muscular dystrophy
community to better identify, understand and reach those who are
currently underrepresented and underserved. Applicants are
encouraged to demonstrate collaboration with minority-led or local
community organizations to overcome barriers that limit the
delivery of health education and support for individuals and
families. The program was launched in 2023 and it awards three
grants of $25,000 (USD) each to U.S.-based non-profit
organizations. Project proposals are reviewed, scored and ranked by
an independent committee comprised of neuromuscular specialists and
patient advocates with expertise in Duchenne, DEIA (diversity,
equity, inclusivity and accessibility), social impact and
health.
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to
transform the lives of patients by establishing a new class of
medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage
intracellular targets that have long been considered inaccessible
and undruggable. The Company’s EEV therapeutics are designed to
enable the efficient intracellular delivery of a wide range of
therapeutics into a variety of organs and tissues, resulting in an
improved therapeutic index. Through its proprietary, highly
versatile and modular EEV platform, Entrada is building a robust
development portfolio of RNA-, antibody- and enzyme-based programs
for the potential treatment of neuromuscular, immunological, ocular
and metabolic diseases, among others. The Company’s lead
oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for
the potential treatment of people living with Duchenne who are exon
44 and 45 skipping amenable, respectively, as well as our partnered
candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).
For more information about Entrada, please visit
our website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media ContactKarla
MacDonaldChief Corporate Affairs
Officerkmacdonald@entradatx.com Patient Advocacy
ContactRegan ShermanHead of Patient
AdvocacyPatientAdvocacy@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Entrada Therapeutics (NASDAQ:TRDA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024